Hydromorphone intrathecal - CNS Therapeutics

Drug Profile

Hydromorphone intrathecal - CNS Therapeutics

Latest Information Update: 27 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CNS Therapeutics
  • Developer Piramal Enterprises
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Pain

Most Recent Events

  • 01 Feb 2018 CNS Therapeutics completes a phase III trial in Pain in USA (Intrathecal) (NCT01709721)
  • 01 Feb 2018 CNS Therapeutics completes a phase III trial for Pain in USA (Intrathecal) (NCT01709747)
  • 20 Mar 2017 Mallinckrodt sold its Intrathecal Therapy Business of drugs for spasticity and pain management to Piramal Enterprises
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top